The Food and Drug Administration (FDA) has approved new drugs, including mobocertinib and amivantamab, for the treatment of advanced epidermal growth factor receptor (EGFR)-expressing non-small cell lung cancer (NSCLC), with many new medicines currently in various stages of research. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.